The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

FDG-PET in Gynecologic Cancer

부인암에서 FDG-PET의 역할

  • Ryu, Sang-Young (Department of Obstetrics & Gynecology, Korea Cancer Center Hospital)
  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Whole-body positron emission tomography (PET) imaging with 18-F deoxyglucose (FDG) is a molecular imaging modality that detects metabolic alteration in tumor cells. In various human cancers, FDG-PET shows a potential clinical benefit in screening, tumor characterization, staging, therapeutic follow-up and detecting recurrence. In gynecologic cancers, FDG-PET is also known to be effective in characterization of adnexal masses, detection of recurrence, and lymph node invasion. This review discusses the clinical feasibility and future clinical application of this imaging modality in patients with cervical cancer, ovarian cancer, and other gynecologic cancers.

Keywords

References

  1. 대한 산부인과 학회. 한국부인암 등록사업 조사보고서(1998.1.1-1998-12.31). 대한산부회지 2001;44:426-59.
  2. Scheidler J, Hricak H, Yu KK, Subak L, SegalMR. Radiological evaluation of lymph nodemetastases in patients with cervical cancer. Ameta-analysis. JAMA 1997;278:1096-101.
  3. Strauss LG, Clorius JH, Schlag P, Lehner B,Kimmig B, Engenhart R, et al. Recurrence ofcolorectal tumors: PET evaluation. Radiology1989;170:329-32.
  4. Anzai Y, Carroll WR, Quint DJ, Bradford CR,Minoshima S, Wolf GT, et al. Recurrence of headand neck cancer after surgery or irradiation:prospective comparison of 2-deoxy-2-[F-18]fluoroD-glucose PET and MR imaging diagnoses.Radiology 1996;200:135-41.
  5. Wahl RL, Quint LE, Cieslak RD, Aisen AM,Koeppe RA, Meyer CR. "Anatometabolic" tumorimaging: fusion of FDG PET with CT or MRI tolocalize foci of increased activity. J Nucl Med1993;34:1190-7.
  6. Wahl RL, Hawkins RA, Larson SM, Hendee WR,Coleman RE, Holden RW, et al. Proceedings of aNational Cancer Institute workshop: PET inoncology--a clinical research agenda. Radiology1994;193:604-6.
  7. Sugawara Y, Eisbruch A, Kosuda S, Recker BE,Kison PV, Wahl RL. Evaluation of FDG PET inpatients with cervical cancer. J Nucl Med1999;40:1125-31.
  8. Grigsby PW, Siegel BA, Dehdashti F. Lymph nodestaging by positron emission tomography in patientswith carcinoma of the cervix. J Clin Oncol2001;19:3745-9.
  9. Landis SH, Murray T, Bolden S, Wingo PA.Cancer statistics, 1998. CA Cancer J Clin1998;48:6-29.
  10. DisaiaPJ, Creasman WT. Clinical Gynecologic Oncology. 6th ed. St.Louis:Mosby;2002.p.53-112.
  11. Fleming ID, Phillips JL, Menck HR, Murphy GP,Winchester DP. The National Cancer Data Basereport on recent hospital cancer program progresstoward complete American Joint Committee onCancer/TNM staging. Cancer 1997;80:2305-10.
  12. Rose PG, Adler LP, Rodriguez M, Faulhaber PF,Abdul-Karim FW, Miraldi F. Positron emissiontomography for evaluating para-aortic nodalmetastasis in locally advanced cervical cancerbefore surgical staging: a surgicopathologic study. JClin Oncol 1999;17:41-5.
  13. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D,Ihling C, Hogerle S, Mix M, et al. Metastaticlymph nodes in patients with cervical cancer:detection with MR imaging and FDG PET.Radiology 2001;218:776-82.
  14. Stehman FB, Bundy BN, DiSaia PJ, Keys HM,Larson IE, Fowler WC. Carcinoma of the cervixtreated with radiation therapy. I. A multi-variateanalysis of prognostic variables in the GynecologicOncology Group. Cancer 1991;67:2776-85.
  15. Vinnicombe SJ, Norman AR, Nicolson V, HusbandIE. Normal pelvic lymph nodes: evaluation with CTafter bipedal lymphangiography. Radiology1995;194:349-55.
  16. DisaiaPJ, Creasman WT. Clinical Gynecologic Oncology. 6th ed. St.Louis:Mosby;2002.p.289-350.
  17. Schroder W, Zinmy M, Rudlowski C, Bull U, RathW. The role of 18F-fluoro-deoxyglucose positronemission tomography (18F-FDG PET) in diagnosis ofovarian cancer. Int J Gynecol Cancer 1999;9:117-122.
  18. Rose PG, Faulhaber P, Miraldi F, Abdul-KarimFW. Positive emission tomography for evaluating acomplete clinical response in patients with ovarianor peritoneal carcinoma: correlation with secondlooklaparotomy. Gynecol Oncol 2001;82: 17-21.
  19. Nakamoto Y, Saga T, Ishimori T, Mamede M,Togashi K, Higuchi T, et al. Clinical value ofpositron emission tomography with FDG forrecurrent ovarian cancer. AJR Am J Roentgenol2001;176:1449-54.
  20. Zinmy M, Siggelkow W, Schroder W, Nowak B,Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro2-deoxy-d-glucose positron emission tomography inthe diagnosis of recurrent ovarian cancer. GynecolOncol 2001;83:310-5.
  21. Nakahara T, Fujii H, Ide M, Mochizuki Y, Takahashi W, Yasuda S, et al. F-18 FDG uptake in endometrial cancer. Clin Nucl Med 2001;26:82-3.
  22. Lapela M, Leskinen-Kallio S, Varpula M, GrenmanS, Alanen K, Nagren K, et al. Imaging of uterinecarcinoma by carbon-ll-methionine and PET. JNucl Med 1994;35:1618-23.
  23. Umesaki N, Tanaka T, Miyama M, Kawamura N,Ogita S, Kawabe J, et al. Positron emissiontomography with (18)F-fluorodeoxyglucose of uterinesarcoma: a comparison with magnetic resonanceimaging and power Doppler imaging. GynecolOncol 2001;80:372-7.